CPNP 2019 industry supported symposia are scientific programs developed for educational purposes. All symposia at CPNP 2019 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit. Meals or snack items may be provided at the start of each event. Room capacities at symposia are limited and entrance is granted on a first-come, first-served basis.
Sunday, April 7, 11:30 a.m.-1:15 p.m. (Lunch Provided)
Emerging Mechanisms and Treatments for Depression
- Explain the potential utility of antidepressant agents that act outside of serotonergic neurotransmission
- Explore the mechanisms of action and efficacy of novel antidepressants
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.5 contact hour of knowledge-based continuing education credit from CPNP approved programming. The ACPE number is 0284-9999-19-060-L01-P.
Neuroscience Education Institute
Tuesday, April 9, 6:45-8:30 a.m. (Breakfast Provided)
Changing the Treatment Landscape: Embracing Long-Acting Injectable Antipsychotics
This interactive educational session will provide a comprehensive update on long-acting injectable (LAI) antipsychotic agents and their role in the treatment of schizophrenia. In recent years, the landscape has changed with the increasing use of LAIs as new data tout benefits of these agents over oral treatment in many clinical situations. Recent evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Evidence also suggests the use of these treatments should be offered at an earlier place in illness. Newly FDA-approved long-acting injectable antipsychotic agents may be dosed without oral overlap, paving the way to less burdensome initiation strategies.
This presentation will explore how the psychiatric pharmacist can play an important role in advocating for earlier introduction of LAIs in schizophrenia, evidence-based approaches to LAI selection, and how best to initiate agents and manage maintenance dosing to improve treatment outcomes.
Deanna Kelly, PharmD, BCPP; CPNP Member Activity Chair
Leslie Citrome, MD
Megan J. Ehret, PharmD, MS, BCPP
- Review the evidence base of long-acting injectable antipsychotics (LAI) with regard to hospitalization and relapse.
- Identify the role of LAIs in the treatment continuum and discuss their use earlier in the schizophrenia disease course.
- Compare LAIs with regard to initiation and maintenance dosing.
- Incorporate LAIs into treatment regimens using case-based examples.
- Welcome and Introductions, Pre-test
- An Era of Change of Long Acting Injectable Antipsychotics: Embracing New Evidence and Data
- Deciding Among the Selections: What are the Pros and Cons of the Available LAIs?
- Case Presentations
- Post-test; Audience Q&A with Faculty
In support of improving patient care, Creative Educational Concepts, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy (NABP) CPE Monitor electronic CE tracking system.
Creative Educational Concepts, Inc.
Tuesday, April 9, 12:00-1:45 p.m. (Lunch Provided)
Practical Strategies for Patient Follow-Up and Long-Term VMAT2 Inhibitor Treatment
Stephen Saklad, PharmD, BCPP (Chair)
Rajesh Jain, MD, MPH
- Evaluate the available clinical trial data surrounding the long-term efficacy and tolerability of VMAT2 inhibitors for the treatment of TD
- Outline the discrete dosing schedules and patient population-specific treatment considerations of available VMAT2 inhibitors for the treatment of TD
- Engage in available patient support programs and communication practices that facilitate VMAT2 inhibitor access through the specialty pharmacy and subsequent treatment continuation
- Pre-Activity Survey
- Interactive, Case-Based, Expert Presentation
- Journal Club Discussion: Long-Term Efficacy and Safety of VMAT2 Inhibitors
- Challenges in Long-Term TD Management: Patient Follow-Up Videos and Discussion
- Discussion and Q&A
- Post-Activity Survey & Evaluation
North American Center for Continuing Education (NACCME)